Skip to main content

Juventas Closes $62 Million C Round for CAR-T/Stem Cells/Gene Editing

Juventas Cell Therapy of Beijing closed a Series C financing of over $62 million to develop its lead  CAR-T candidate, stem cell (iPSCs) technology and gene editing platform. In 2019, Juventas out-licensed global rights to CNCT19, a CD19 CAR-T treatment, to CASI Pharma in return for an $11.6 million CASI investment. Juventas remains in control of clinical trials of the CAR-T in leukemia and lymphoma patients. The C round was jointly led by CICC Capital's fund and Oceanpine Healthcare Fund. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.